78 related articles for article (PubMed ID: 26243193)
1. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
2. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
van Maaren MC; van Steenbeek CD; Pharoah PDP; Witteveen A; Sonke GS; Strobbe LJA; Poortmans PMP; Siesling S
Eur J Cancer; 2017 Nov; 86():364-372. PubMed ID: 29100191
[TBL] [Abstract][Full Text] [Related]
3. Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.
Alkner S; Tang MH; Brueffer C; Dahlgren M; Chen Y; Olsson E; Winter C; Baker S; Ehinger A; Rydén L; Saal LH; Fernö M; Gruvberger-Saal SK
Breast Cancer Res; 2015 Aug; 17(1):102. PubMed ID: 26242876
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre.
Syed BM; Al-Khyatt W; Johnston SJ; Wong DW; Winterbottom L; Kennedy H; Green AR; Morgan DA; Ellis IO; Cheung KL
Br J Cancer; 2011 Apr; 104(9):1393-400. PubMed ID: 21448163
[TBL] [Abstract][Full Text] [Related]
5. DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.
Powe DG; Dhondalay GK; Lemetre C; Allen T; Habashy HO; Ellis IO; Rees R; Ball GR
PLoS One; 2014; 9(1):e84428. PubMed ID: 24392136
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen receptor low positive breast cancer: associations with prognosis.
Skjervold AH; Valla M; Bofin AM
Breast Cancer Res Treat; 2023 Oct; 201(3):535-545. PubMed ID: 37462784
[TBL] [Abstract][Full Text] [Related]
7. Relation of risk of contralateral breast cancer to the interval since the first primary tumour.
Rubino C; Arriagada R; Delaloge S; Lê MG
Br J Cancer; 2010 Jan; 102(1):213-9. PubMed ID: 19920826
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.
Kramer I; Hooning MJ; Mavaddat N; Hauptmann M; Keeman R; Steyerberg EW; Giardiello D; Antoniou AC; Pharoah PDP; Canisius S; Abu-Ful Z; Andrulis IL; Anton-Culver H; Aronson KJ; Augustinsson A; Becher H; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bogdanova NV; Bojesen SE; Bolla MK; Bonanni B; Brauch H; Bremer M; Brucker SY; Burwinkel B; Castelao JE; Chan TL; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Choi JY; Clarke CL; ; Collée JM; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; Dos-Santos-Silva I; Dunning AM; Dwek M; Eccles DM; Evans DG; Fasching PA; Flyger H; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Giles GG; Goldgar DE; González-Neira A; Haiman CA; Håkansson N; Hamann U; Hartman M; Heemskerk-Gerritsen BAM; Hollestelle A; Hopper JL; Hou MF; Howell A; ; ; Ito H; Jakimovska M; Jakubowska A; Janni W; John EM; Jung A; Kang D; Kets CM; Khusnutdinova E; Ko YD; Kristensen VN; Kurian AW; Kwong A; Lambrechts D; Le Marchand L; Li J; Lindblom A; Lubiński J; Mannermaa A; Manoochehri M; Margolin S; Matsuo K; Mavroudis D; Meindl A; Milne RL; Mulligan AM; Muranen TA; Neuhausen SL; Nevanlinna H; Newman WG; Olshan AF; Olson JE; Olsson H; Park-Simon TW; Peto J; Petridis C; Plaseska-Karanfilska D; Presneau N; Pylkäs K; Radice P; Rennert G; Romero A; Roylance R; Saloustros E; Sawyer EJ; Schmutzler RK; Schwentner L; Scott C; See MH; Shah M; Shen CY; Shu XO; Siesling S; Slager S; Sohn C; Southey MC; Spinelli JJ; Stone J; Tapper WJ; Tengström M; Teo SH; Terry MB; Tollenaar RAEM; Tomlinson I; Troester MA; Vachon CM; van Ongeval C; van Veen EM; Winqvist R; Wolk A; Zheng W; Ziogas A; Easton DF; Hall P; Schmidt MK
Am J Hum Genet; 2020 Nov; 107(5):837-848. PubMed ID: 33022221
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of developing contralateral breast cancer after first primary breast cancer treatment.
Avatefi M; HadavandSiri F; Nazari SSH; Akbari ME
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1927. PubMed ID: 37919558
[TBL] [Abstract][Full Text] [Related]
10. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes.
Yoshida N; Omoto Y; Inoue A; Eguchi H; Kobayashi Y; Kurosumi M; Saji S; Suemasu K; Okazaki T; Nakachi K; Fujita T; Hayashi S
Cancer Sci; 2004 Jun; 95(6):496-502. PubMed ID: 15182430
[TBL] [Abstract][Full Text] [Related]
11. Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance.
Makhlouf S; Quinn C; Toss M; Alsaleem M; Atallah NM; Ibrahim A; Rutland CS; Mongan NP; Rakha EA
Eur J Cancer; 2024 Jan; 197():113473. PubMed ID: 38103327
[TBL] [Abstract][Full Text] [Related]
12. H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer.
Xiao CK; Ren Y; Chen Q; Yang Y; Tang L; Xu L; Ren Z
Epigenetics; 2024 Dec; 19(1):2343593. PubMed ID: 38643489
[TBL] [Abstract][Full Text] [Related]
13. Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.
Giardiello D; Hauptmann M; Steyerberg EW; Adank MA; Akdeniz D; Blom JC; Blomqvist C; Bojesen SE; Bolla MK; Brinkhuis M; Chang-Claude J; Czene K; Devilee P; Dunning AM; Easton DF; Eccles DM; Fasching PA; Figueroa J; Flyger H; García-Closas M; Haeberle L; Haiman CA; Hall P; Hamann U; Hopper JL; Jager A; Jakubowska A; Jung A; Keeman R; Koppert LB; Kramer I; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Manoochehri M; Mariani L; Nevanlinna H; Oldenburg HSA; Pelders S; Pharoah PDP; Shah M; Siesling S; Smit VTHBM; Southey MC; Tapper WJ; Tollenaar RAEM; van den Broek AJ; van Deurzen CHM; van Leeuwen FE; van Ongeval C; Van't Veer LJ; Wang Q; Wendt C; Westenend PJ; Hooning MJ; Schmidt MK
Breast Cancer Res Treat; 2020 Jun; 181(2):423-434. PubMed ID: 32279280
[TBL] [Abstract][Full Text] [Related]
14. The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer.
Kay C; Martinez-Perez C; Dixon JM; Turnbull AK
J Pers Med; 2023 Oct; 13(10):. PubMed ID: 37888087
[TBL] [Abstract][Full Text] [Related]
15. Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women.
Carleton N; Nasrazadani A; Gade K; Beriwal S; Barry PN; Brufsky AM; Bhargava R; Berg WA; Zuley ML; van Londen GJ; Marroquin OC; Thull DL; Mai PL; Diego EJ; Lotze MT; Oesterreich S; McAuliffe PF; Lee AV
Lancet Healthy Longev; 2022 Jan; 3(1):e54-e66. PubMed ID: 35047868
[TBL] [Abstract][Full Text] [Related]
16. Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival.
Newcombe PJ; Raza Ali H; Blows FM; Provenzano E; Pharoah PD; Caldas C; Richardson S
Stat Methods Med Res; 2017 Feb; 26(1):414-436. PubMed ID: 25193065
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer.
Khan S; Fagerholm R; Kadalayil L; Tapper W; Aittomäki K; Liu J; Blomqvist C; Eccles D; Nevanlinna H
Oncotarget; 2018 Jan; 9(3):4249-4257. PubMed ID: 29423119
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic biomarkers in breast tumours.
Krystel-Whittemore M; Tan PH; Wen HY
Pathology; 2024 Mar; 56(2):186-191. PubMed ID: 38212230
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcome measurement.
Goodare H
J R Soc Med; 2010 Jul; 103(7):264. PubMed ID: 20595529
[No Abstract] [Full Text] [Related]
20. Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Johnston SR
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26251289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
